Ixazomib combination demonstrates efficacy in relapsed and refractory myeloma patients

Results from a Phase II study, recently published in Leukaemia, show that the oral combination of ixazomib (Ninlaro®), pomalidomide (Imnovid®) and dexamethasone is effective in relapsed and refractory myeloma patients. All patients in this study were refractory to lenalidomide (Revlimid®). 48% of patients who received the recommended dose of ixazomib (4mg) achieved a partial response or…

Details

Pomalidomide combination shows efficacy in relapsed and refractory myeloma patients with renal impairment

Published in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…

Details

Results from Phase III ALCYONE trial published

The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…

Details

Phase III pomalidomide trial reaches primary endpoint

Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…

Details

Carfilzomib combinations demonstrate overall survival benefit in relapsed and refractory myeloma

Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…

Details

Results from TEAMM clinical trial reported

Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…

Details

Carfilzomib treatment associated with cardiovascular events in myeloma patients

A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…

Details

Myeloma UK study of patient preferences published

Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…

Details